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ABSTRACT 1 
 2 
Background: People with depression/anxiety are twice as likely to smoke and are less responsive to 3 
standard tobacco treatments, leading to a reduced life expectancy of 14 years compared to people 4 
without depression/anxiety. However, this group of smokers are motivated to quit and as a result of 5 
quitting smoking their depression/anxiety is likely to improve. In England, people with 6 
depression/anxiety are referred to a primary care-based psychological therapies service known as 7 
‘Improving Access to Psychological Therapies’ (IAPT), which could offer smoking cessation treatment 8 
as part of usual care but currently does not. In this study we aim to: 1) To establish the feasibility and 9 
acceptability of delivering a smoking cessation treatment alongside IAPT: 2) To establish the 10 
feasibility of a multi-centre randomised trial to compare the combined smoking cessation and IAPT 11 
treatment to usual IAPT treatment alone. 12 
 13 
Methods: A randomised and controlled, multi-centre trial to test the acceptability, feasibility and 14 
implementation of smoking cessation treatment as offered alongside usual IAPT care, compared to 15 
usual care alone, with nested qualitative methods. We will include adult daily smokers with 16 
depression/anxiety, who would like help to quit smoking and are about to start IAPT treatment. 17 
Follow-up will be conducted at 3 months. The main outcome will be retention in the smoking 18 
cessation treatment. Secondary outcomes: smoking-related (biochemically-verified 7-day point 19 
prevalence smoking cessation, number of cigarettes smoked per day, Heaviness of Smoking Index), 20 
mental health-related (PHQ-9), service-related (number of “Did Not Attends”, number of planned 21 
and completed IAPT sessions), acceptability and feasibility (participant and clinician acceptability and 22 
satisfaction of intervention as assessed by questionnaires and qualitative interviews, interviews will 23 
also explore acceptability and feasibility of data collection procedures, and impact of smoking 24 
cessation treatment on usual care and psychological recovery), implementation-related 25 
(intervention delivery checklist, qualitative analysis of intervention delivery). 26 
 27 
Discussion: If the intervention is shown to be acceptable, feasible and suitably implemented, we can 28 
conduct a randomised controlled trial. In a future trial, we would examine whether adding smoking 29 
cessation treatment increases smoking abstinence and improves depression and anxiety more than 30 
usual care, which would lead to long-term health improvement.  31 
 32 
Study Registration: ISRCTN99531779 33 
  34 
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BACKGROUND 1 
 2 
Smoking is the world’s leading cause of preventable illness and death1. One in every two smokers 3 
will die of a smoking-related disease, unless they quit2,3. In high income countries smoking 4 
prevalence has decreased from 46% during the 1970s to about 19% in recent years4–6. However, 5 
smoking prevalence amongst people with mental disorders has declined only slightly and is currently 6 
around 37%7.  In the UK 30% to 40% of all people with depression/anxiety smoke7. They are more 7 
heavily addicted, suffer from worse withdrawal7–10, and experience a 19% reduction in the odds of 8 
quitting (odds ratio 0.81, 95% CI: 0.67 to 0.97)10; even though they are motivated to quit 11,12. These 9 
inequalities contribute to a reduction in life-expectancy of up to 13.6 years for people with 10 
depression/anxiety compared to the general population13,14. 11 
 12 
Traditionally, mental health and addictive behaviours have been treated separately. More recently, 13 
there has been a movement towards interventions that target both mental health and addiction15–17. 14 
Studies in patients with severe mental disorders or alcoholism have shown that treating addiction 15 
and mental health in parallel results in meaningful improvements in both18–21. Van der Meer and 16 
colleagues conducted a Cochrane review of smoking cessation treatments for people with current 17 
and historical depression22, and found that adding psychosocial mood management to usual smoking 18 
cessation treatment (e.g., nicotine replacement therapy) moderately increased cessation rates when 19 
compared to usual smoking treatment alone (risk ratio of 1.47; 95% confidence interval: 1.13 to 20 
1.92)23; thus highlighting the importance of psychological support during a quit attempt for this 21 
group.  22 
 23 
Recent evidence suggests that stopping smoking is associated with mental health benefits equal to 24 
anti-depressant treatment24. In England, people with depression/anxiety have access to 25 
psychological therapy services, known as ‘Improving Access to Psychological Therapies’ (IAPT), in 26 
which service users receive psychological therapies for depression and anxiety. IAPT may be an ideal 27 
platform for delivering smoking cessation treatment. However, there have been no trials comparing 28 
the effectiveness of offering smoking cessation treatment alongside usual care 25, and therefore it is 29 
unknown if such a treatment is feasible and acceptable to service users and therapists, and can be 30 
implemented into the service. We have spent the last 9 months designing an intervention with 31 
stakeholders to enhance intervention suitability. In this study we aim to: 1) assess the feasibility of 32 
recruiting and retaining participants, collecting data required for a full-sized RCT, randomisation 33 
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procedures; and 2) the acceptability of data collection procedures and the smoking cessation 1 
treatment as delivered alongside usual IAPT care, as perceived by PWPs and study participants.   2 
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METHODS 1 
 2 
Design 3 
A randomised and controlled multicentre feasibility trial with nested qualitative research to test the 4 
acceptability, feasibility and implementation of smoking cessation treatment offered alongside usual 5 
psychological care. The study has been registered on ISRCTN99531779. Any changes to the methods 6 
outlined in this protocol will be outlined in the report of the study findings. 7 
 8 
 9 
Ethical review 10 
This study received ethics approval from the National Health Service Research Ethics Committee on 11 
19/03/2018 (IRAS ID: 239339). In the case that there are any protocol modifications these will be 12 
submitted for ethical review. 13 
 14 
 15 
Setting 16 
This is a multicentre study involving two Improving Access to Psychological Therapies (IAPT) sites in 17 
the United Kingdom. IAPT is a National Health Service primary-care based psychological therapy 18 
service (https://www.england.nhs.uk/mental-health/adults/iapt/). IAPT offers low and high intensity 19 
evidence-based therapies (e.g. cognitive behavioural therapy (CBT)) to people with common mental 20 
disorders. Psychological treatment is delivered by therapists named “psychological wellbeing 21 
practitioners” (PWPs), and usually consists of six, 30-45-minute sessions, delivered over the 22 
telephone or face-to-face (further details below). 23 
 24 
 25 
Project timeline 26 
The study will be undertaken over 18 months, and the final follow-up will be in September 2019 (see 27 
online appendix for a detailed study timeline, and Table 1 and Figure 1 for a “Standard Protocol 28 
Items: Recommendations for Interventional Trials (SPIRIT)26” schedule of enrolment, interventions 29 
and assessments, and study flow chart). 30 
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Eligibility criteria 1 
Participants (IAPT service users) 2 
Inclusion criteria: 3 
• Aged 18 years or older; 4 
• Has current diagnosis of depression (clinician administered PHQ-9 score of ≥ 10) and/or 5 
anxiety (clinician administered GAD-7 score of ≥8) (note: other mental health 6 
comorbidities are allowable); 7 
• Self-reported, daily tobacco smoker of at least 1 year; 8 
• Interested in receiving help to quit smoking tobacco; 9 
• Eligible for IAPT treatment on a one-to-one basis over the telephone or face-to-face; 10 
• About to start psychological therapy for depression/anxiety in IAPT.  11 
Exclusion criteria: 12 
• Already started IAPT treatment; 13 
• Considered too unwell by research or clinical team (i.e. the IAPT provider); 14 
• Pregnant or breastfeeding. 15 
 16 
Psychological wellbeing practitioners 17 
Inclusion criteria: 18 
• Aged 18 years or older; 19 
• Have provided psychological treatment to people with depression/anxiety in IAPT for at 20 
least 2 years; 21 
• Available to attend training in delivering the smoking cessation intervention; 22 
• Non- or ex-smoker. 23 
 24 
 25 
Withdrawal of participants 26 
Patient and PWP participants can withdraw from the study at any time, and they can withdraw their 27 
data from the study at any time during the study period. 28 
 29 
 30 
Payments to participants 31 
Participants will not be paid for their contribution to the study.  32 
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Intervention arm 1 
In both the intervention and control groups, participants will receive CBT, typically lasting 30-45 2 
minutes per session, delivered over 6 sessions. In the intervention group only, participants will 3 
receive a multi-component smoking cessation treatment that includes behavioural, psychological 4 
and pharmacological support. PWPs will deliver the treatment as parallel to usual IAPT care (see 5 
Table 2). The smoking cessation treatment package is an adapted version of the National Centre for 6 
Smoking Cessation and Training’s (NCSCT) standard treatment programme27. The NCSCT standard 7 
treatment programme is based on the most up-to-date evidence available, is supported by the 8 
National Institute for Clinical Excellence and is proven to be cost-effective in NHS settings28,29. The 9 
smoking cessation treatment will be delivered over the telephone or face-to-face (i.e., depending on 10 
usual care), and will be delivered on an individual basis. Based on interviews and consultation with 11 
stakeholders, the intervention has been altered to best fit IAPT usual care and client needs, while 12 
being mindful of the NCSCT’s standard treatment programme. 13 
 14 
Duration and number of sessions: Participants will receive 5-15 minutes of smoking cessation 15 
treatment per IAPT appointment, delivered over 6 IAPT usual care appointments. In Bristol PWPs will 16 
deliver smoking cessation treatment within the usual care timeframe. In Oxford PWPs will be 17 
allocated an extra 5-15 minutes per IAPT appointment to deliver the smoking cessation treatment. 18 
We predict that treatment will last approximately 12 weeks; however, this is subject to the progress 19 
of the participants IAPT care. During the first 2 IAPT appointments, 10-15 minutes will be allocated 20 
to delivering the smoking cessation treatment, and the remaining time will be used to deliver IAPT 21 
usual care. For the following 4 IAPT appointments, 5-10 minutes will be used to deliver the smoking 22 
cessation treatment, and the remaining time will be used to deliver IAPT usual care.  23 
 24 
Behavioural and psychological components: PWPs will offer behavioural support as outlined in the 25 
standard treatment programme written by the National Centre for Smoking Cessation and 26 
Training27. See Table 2 for an outline of the modified version of the standard treatment programme 27 
that will be delivered in this study. In addition to behavioural support, participants will receive 28 
psychoeducation about smoking and mental health. New evidence suggests that stopping smoking is 29 
associated with mental health benefits, potentially equivalent to taking anti-depressants24. This can 30 
partially be explained by breaking the smoking withdrawal cycle – in sum, nicotine has a short half-31 
life, and smokers start to experience the psychological symptoms of withdrawal soon after having a 32 
cigarette, for example symptoms of low mood and anxiety. Therefore, the smoker is in a constant 33 
state of withdrawal, with short periods of relief only when they are actively smoking and shortly 34 
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after finishing a cigarette. It may be that smokers mistake the ability of smoking to relieve 1 
withdrawal symptoms to its ability to relieve stress and low mood30,31. Participants will receive an 2 
information pack about quitting smoking and mental health via email, leaflet or post. 3 
 4 
Nicotine replacement therapy (NRT): NRT will be provided at cost of prescription, or free-of-charge 5 
(depending on site), alongside behavioural support to use NRT (NCSCT, and the British National 6 
Formulary27,32). NRT will be posted or participants will be given a prescription request to present 7 
their local pharmacy (i.e. depending if IAPT care is delivered over the telephone, or face-to-face). In 8 
both sites participants will receive an information pack that includes text and video instructions on 9 
how to take the NRT. Participants who self-report having diabetes mellitus, renal impairment or 10 
hepatic impairment will be referred to their GP or pharmacy prescriber for NRT32. All NRT vouchers 11 
and products have been provided by local smoking cessation services. 12 
 13 
Participants will be provided with two NRT products, and the participant will have the opportunity to 14 
alter the dose or type of NRT27. As per the NCSCT’s standard smoking cessation treatment 15 
programme, participants will be provided with nicotine patches, and the strength will depend on 16 
level of nicotine dependency as assessed using the Heaviness of Smoking Index33. A second NRT 17 
product will be recommended to help combat cravings – participants will have a choice of a lozenge, 18 
gum, microtab, nasal spray, mouth-spray, mini lozenges, or strips, with strength depending on level 19 
of nicotine dependency (as assessed using the Heaviness of Smoking Index). See online appendix for 20 
list of NRT products available.  21 
 22 
Varenicline: If the participant prefers not to use NRT or has previously used NRT as part of a 23 
behavioural treatment and failed to quit, they will have the option of using varenicline, pending 24 
confirmation from their GP/pharmacy. The participant’s GP or pharmacist prescriber will prescribe 25 
varenicline at their discretion. Participants will receive behavioural support for use of varenicline as 26 
outlined by the NCSCT27 and in Table 2. 27 
 28 
E-cigarettes: PWPs will provide behavioural support to participants who choose to use e-cigarettes 29 
to aid their quit attempt. This follows recommendations from Public Health England34. However, the 30 
study will not fund the purchase of e-cigarettes or accessories.  31 
 32 
Differences between NCSCT’s standard treatment programme for smoking cessation, and the 33 
smoking cessation treatment offered in this study: To tailor the smoking cessation treatment to IAPT 34 
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usual care, we interviewed PWPs, managers and service users (NHS National Research Ethics Service 1 
review ID:225399. i.e., under write-up) and consulted with current and prospective commissioners 2 
for IAPT services. Based on interviews and consultations we modified the Standard Treatment 3 
Programme as follows: 4 
1. Shortened total treatment time from 110 minutes to 40 to 70 minutes to meet IAPT service 5 
requirements. 6 
2. CO monitoring will not be part of the intervention in one of the sites, as IAPT care is 7 
predominately telephone-based in one of the two sites. 8 
3. There will be an emphasis on addressing the relationships between smoking, the withdrawal 9 
cycle and mental health. 10 
 11 
Integrating smoking cessation treatment into IAPT usual care: IAPT is based on a “guided self-help” 12 
model. The main aim of guided self-help is to support the client in learning how to make positive 13 
changes to their behaviour and thinking, to help improve their mental health. With support from 14 
their PWP, service users learn a toolkit of coping strategies to help them to become their own 15 
therapist, so that they can manage their mood effectively and prevent future setbacks. Interviews 16 
with PWPs and IAPT service users, and consultations with service managers have identified that 17 
there are many used psychological theories and techniques that PWPs regularly use that provide 18 
PWPs with opportunities to deliver behavioural and psychological support to help service users to 19 
stop smoking; for example, motivational interviewing, psychoeducation, and behavioral activation. 20 
 21 
 22 
Control arm 23 
Participants in the control arm will receive IAPT usual care, plus contact details for their local 24 
Smoking Cessation Service during their final IAPT appointment 25 
 26 
 27 
Psychological wellbeing practitioner training programme 28 
A maximum of 10 PWPs per site will be trained to deliver the treatment. PWPs will take part in the 29 
following training:  30 
1) NCSCT level 1 online training and assessment programme;  31 
2) NCSCT level 2 face-to-face training; 32 
3) An overview about the importance of randomised trial methodology and study procedures 33 
(e.g. data recording); 34 
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4) A researcher will visit each service once a month and to listen in on sessions and offer 1 
feedback to PWPs.  2 
 3 
 4 
Outcomes 5 
The trial aims to assess the feasibility of recruiting and retaining participants, collecting data 6 
required for a full-sized RCT, randomisation procedures, and the acceptability of data collection 7 
procedures and the smoking cessation treatment as delivered alongside usual IAPT care, as 8 
perceived by PWPs and study participants. 9 
 10 
Main acceptability and feasibility outcome: 11 
• Study completers: Participants will be considered a completer if they: a) continue with 12 
smoking cessation treatment up until the point of smoking cessation, a quit attempt, or 13 
completion of IAPT care. The proportion of study completers will be calculated by: 14 
 15 
𝑁 𝑠𝑡𝑢𝑑𝑦 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑟𝑠
𝑁 𝑟𝑎𝑛𝑑𝑜𝑚𝑖𝑠𝑒𝑑 𝑎𝑡 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 16 
 17 
Secondary acceptability and feasibility outcomes  18 
• Recruitment in to the trial 19 
• Retention in smoking cessation treatment 20 
• Participant and PWP acceptability and satisfaction of smoking cessation treatment 21 
(Modified version of the Stop Smoking Service Client Satisfaction Survey39, and Modified 22 
version of a clinician self-report intervention acceptability questionnaire40) 23 
• Qualitative Interviews with PWPs will explore PWP perceptions of:  24 
o Participant acceptance of the smoking cessation treatment 25 
o Acceptability of data collection procedures 26 
o Positive and negative impacts of smoking cessation treatment on IAPT usual care 27 
• Qualitative Interviews with participants will explore participant perceptions of:  28 
o PWP ability to deliver the smoking cessation treatment 29 
o Acceptance of treatment 30 
o Positive and negative impacts of treatment on IAPT care and mental health recovery  31 
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Implementation outcomes: 1 
• Checklist: We will listen to a proportion of smoking cessation treatment sessions and 2 
note which intervention components were delivered or not (Table 2); 3 
• Observations & listening to intervention delivery recordings. 4 
 5 
We will check data completeness for the following outcomes: 6 
Smoking related:  7 
• Carbon monoxide (CO)-verified 7-day point prevalence smoking cessation (i.e., validated 8 
by exhaled carbon monoxide concentration of <10 parts per million (ppm)35. CO testing 9 
will be available on both sites via a 3-month follow-up home visit; 10 
• Number of cigarettes per day; 11 
• Heaviness of Smoking Index (HSI)36. 12 
Mental health:  13 
• Patient Health Questionnaire (PHQ-9)37 score; 14 
Service:  15 
• Number of “Did Not Attends”; 16 
• Number of planned, completed and missed IAPT appointments. 17 
 18 
 19 
Sample size 20 
Trial: Assuming a sample size of 100 participants at follow-up we used a standard formula to 21 
calculate the binomial exact confidence interval41,42. The study will have sufficient power to estimate 22 
that: 40% or more participants will continue with smoking cessation treatment in the intervention 23 
arm with a 95% confidence interval of 26% to 55% (i.e., assuming the true rate is 40%).  24 
 25 
Therefore, assuming that about 36% of participants will be lost to follow-up43,44, this study will 26 
require a sample size of 157 at baseline:  27 
(i.e.,157 − (157 (
36
100
)) = 100)) 28 
 29 
Interviews: We will aim to interview 10 PWPs who deliver the smoking cessation treatment, and 20 30 
trial participants45. We will use a purposeful sampling and aim for variation across the sites and 31 
participant final smoking status. 32 
Integrating smoking cessation treatment into IAPT care 
12 
 
 1 
 2 
Recruitment and consent procedures 3 
Trial: Researchers will search for potentially eligible participants via client management software. 4 
Potentially eligible participants will be posted study information at least 2-weeks prior to their first 5 
IAPT appointment and contacted by a researcher prior to their first IAPT appointment to discuss 6 
eligibility and gain oral informed consent. Trial consent form is available in the online appendix. 7 
 8 
Audio recording of treatment session: Sessions are recorded as part of IAPT usual care, written 9 
informed consent is gained on the same day as treatment by PWPs. 10 
 11 
Interviews:  During the 3 month follow-up, trial participants will be recruited into interviews. We will 12 
conduct interviews with 10 participants in the intervention arm, or until saturation is reached.. PWPs 13 
will be recruited into interviews after they’ve finished delivering the intervention to their final 14 
participant. We will conduct interviews with all PWPs involved in intervention delivery (i.e., 10 PWPs 15 
across the sites). Written informed consent will be obtained on the day of the interview. 16 
 17 
 18 
Randomisation and intervention assignment methods 19 
Sequence generation: The randomisation sequence will be generated by a statistician using Stata 20 
software. Randomisation will be stratified by site and blocked, and participants will be randomised 21 
using a 1:1 algorithm to ensure an equal number of participants in the treatment and control arms.  22 
 23 
Allocation concealment mechanism: Allocation concealment will be ensured as the randomisation 24 
code will not be released until the IAPT client has been recruited into the trial, which takes place 25 
after participant eligibility has been assessed, participant identifier has been recorded and consent 26 
gained to take part in the trial and to being randomly allocated to treatment condition. 27 
 28 
Implementation: Randomisation will be requested via RedCap by the researcher who recruited and 29 
consented the participant into the trial. RedCap will send a response to the researcher informing 30 
them which treatment the participant will be receiving. Randomisation can only be requested once 31 
and after participant identifier, eligibility and consent has been recorded, and therefore 32 
implementation cannot be influenced by the PWP, participant, the research or clinical team 33 
 34 
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 1 
Blinding 2 
Due to the nature of the intervention, it is not possible to blind participants and PWPs who deliver 3 
the intervention. Quantitative 3 month follow-up outcome assessments will be conducted by a 4 
researcher who will be blinded to treatment allocation. Qualitative interviews will be conducted 5 
after quantitative outcomes assessment, as it is possible that the researcher will become unblinded 6 
during interviews. Outcome assessor blinding will also be verified by self-report at final follow-up. 7 
 8 
 9 
Data collection 10 
See online appendix for full data management plan. 11 
 12 
Quantitative data collection: Table 1 and Figure 1 present a schedule of data collection. Most 13 
participant data will be collected as part of usual care. Baseline and 3 month follow-up data will be 14 
collected by a researcher. Usual care data will be recorded by PWPs on the patient management 15 
system and then extracted and input into RedCap by researchers (Table 3).  16 
 17 
Qualitative data collection: We will collect two types of qualitative data:  18 
1) Recordings of intervention delivery 19 
2) Post-intervention interviews with PWPs and participants.  20 
 21 
Intervention delivery recordings will be taken as part of usual care, and only relevant sections, as 22 
decided by a researcher, will be used for analysis (i.e. where smoking cessation treatment is being 23 
delivered). We will have access to these recordings and will sample 30 random sessions to assess 24 
implementation.  25 
 26 
Interviews will be conducted by a researcher, ideally in-person, but also over the telephone upon 27 
request. Interviews will last no longer than 60 minutes and will be conducted using flexible topic 28 
guides to ensure that the same broad topics are covered in all interviews, while allowing flexibility 29 
for interviewees to introduce new issues46. Topic guides will be modified as necessary throughout 30 
the course of the interviews to reflect findings as they emerge. The interviewer will use open-ended 31 
questioning techniques to elicit participants’ own experiences and views and participants will be 32 
asked to provide examples to avoid reliance on ‘hypothetical’ accounts. Interviews will be 33 
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anonymised to protect confidentiality. All interview data will be transcribed using a University 1 
approved service. 2 
 3 
 4 
Post-trial care 5 
If the participant would like to use nicotine products beyond their IAPT treatment, they will be able 6 
to obtain a prescription from their GP or local smoking cessation service. Participants will be 7 
required to pay a prescription dispensing fee for varenicline, unless they are exempt from paying for 8 
their prescriptions through the NHS. If the participant was not successful in their quit attempt the 9 
PWP will provide them with contact details to a local Stop Smoking Service.  10 
 11 
 12 
Adverse events 13 
PWPs will check in with participants about the progress of their quit attempt and the stop smoking 14 
medication that they are using. In the case that the participant is experiencing any unusual 15 
symptoms or events, PWPs will use the NHS “Decision Tree for Adverse Event Reporting” (See 16 
appendix) to class and action adverse events (AE) (i.e., any unfavorable and unintended signs, 17 
symptoms or a disease associated with treatment). AEs will be recorded in the study file with a note 18 
that will identify when the event occurred, the details of the AE, any potential study relation, action 19 
taken and resolution / closure of the AE. An assessment of seriousness will be made and will be 20 
reported to a Research Governance Officer.  21 
 22 
 23 
Patient and public involvement 24 
During study conceptualisation, the research aims and study design were peer reviewed by several 25 
members of the public and was presented to the UK Centre for Tobacco and Alcohol Studies 26 
Smokers’ Panel, and the Elizabeth Blackwell Institute’s Public Advisory Group for feedback. In 27 
general, the study’s concept was well received, understood, and thought to be an important area of 28 
research. We will invite a patient member to trial management meetings, and to involve patient and 29 
public panels in study analysis and dissemination. 30 
 31 
 32 
Participant benefit 33 
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By taking part in this research participants will assist in the planning of an intervention to help others 1 
quit smoking. Also, by choosing to take part, participants will increase their chances of quitting 2 
smoking, which is the single most important change one can make to improve their health. 3 
 4 
 5 
Quantitative analysis 6 
Analyses will be conducted in Stata. 7 
 8 
Primary and secondary feasibility measures 9 
 10 
We will present screened, randomised, treated, and followed up for primary outcome in a 11 
CONSORT-style flow chart. The proportion of study completers, by trial arm will be calculated as: 12 
 13 
𝑁 𝑠𝑡𝑢𝑑𝑦 𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒𝑟𝑠
𝑁 𝑟𝑎𝑛𝑑𝑜𝑚𝑖𝑠𝑒𝑑 𝑎𝑡 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
 14 
 15 
 16 
Piloting main trial outcomes 17 
The outcome measures which we intend to include in the main trial will be piloted in this feasibility 18 
study. We will present summary statistics by study group for each measure at each assessment 19 
point. Estimated intervention effects will be presented with 95% confidence intervals, these 20 
estimates being calculated using regression models that include study site, the patient’s PWP, and 21 
baseline PHQ-9 score. Linear regression will estimate differences in means for continuous measures, 22 
and logistic regression will estimate odds ratios for binary measures. As this is a feasibility study, 23 
these estimates will be too imprecise to support definitive conclusions, but will be inspected for 24 
evidence of a benefit of combining the smoking cessation intervention with IAPT. 25 
 26 
Sensitivity analyses: 1) We will conduct home visits with all participants to CO-verify self-reported 27 
quits, however it is possible that some participants may decline/be unavailable for a home-visit and 28 
therefore in those cases we will not be able to obtain biological data. To account for this, we will 29 
compare estimates derived from CO-verified and self-reported 7-day point prevalence smoking 30 
cessation. 2) Where data permit we compare the approaches in Bristol and Oxford for their 31 
acceptability and feasibility. 32 
 33 
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We will develop a full statistical plan ahead of data analysis.   1 
 2 
 3 
Qualitative analysis 4 
We will conduct two qualitative analyses: 1) analysis of intervention delivery recordings, and 2) 5 
analysis of qualitative interviews with PWPs and study participants. 6 
 7 
Qualitative data will be analysed using a thematic approach, following guidance outlined by Braun 8 
and Clarke46; thematic analysis will allow for both anticipated themes (i.e., deductive coding) and 9 
emergent themes (i.e., inductive coding). All data will be anonymised, and to ensure quality of data 10 
transcription a researcher will do a 50% check of audio data against the transcripts. N-Vivo software 11 
will be used to code and apply the analytical framework. 12 
 13 
Coding: One researcher will read the transcripts in full and will re-listen to the audio recordings 14 
before coding the transcripts, then two researchers will read and do preliminary coding of a subset 15 
(i.e., a paraphrase, label). Codes can refer to substantive things (e.g., behaviours, incidents, 16 
structures), values (e.g., beliefs about smoking, treatment, rights), emotions (e.g., sadness, 17 
happiness) and more methodological elements (e.g., interviewee found something difficult to 18 
explain, or became emotional)47.  19 
 20 
Developing a framework: After coding three transcripts, researchers involved in coding will meet to 21 
compare the labels that they have applied and agree on a set of codes to apply to all remaining 22 
transcripts. Codes will be grouped together into categories, which are then clearly defined. The first 23 
framework will act as a working analytical framework as this may change after further coding of new 24 
transcripts. After initial coding of all interviews using the working analytical framework, all 25 
interviews will be re-read, and codes re-examined for overlap and distinctiveness and a final 26 
framework of themes agreed. This framework will form the basis for the structuring and 27 
presentation of themes when writing up the qualitative findings.  28 
 29 
Applying the analytical framework: The framework will be applied by indexing interview transcripts 30 
using the existing categories and codes. Each code will be assigned an abbreviation and will be given 31 
a description, to ensure consistent application of codes across the dataset. We will adopt a flexible 32 
approach, and some codes may be grouped/merged or split as additional transcripts are coded.   33 
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DISCUSSION 1 
In this protocol we describe a feasibility study looking both at the feasibility of the intervention, and 2 
at the feasibility of comparing the new intervention with IAPT alone in a full randomised controlled 3 
trial. 4 
 5 
Strengths and limitations 6 
In our previous study we interviewed PWPs, service managers and service users (NHS National 7 
Research Ethics Service review ID:225399. i.e., under write-up) and consulted with current and 8 
prospective commissioners for IAPT services in aim of tailoring the smoking cessation treatment to 9 
IAPT usual care. The smoking cessation treatment package is an adapted version of the National 10 
Centre for Smoking Cessation and Training’s (NCSCT) standard treatment programme27. The NCSCT 11 
standard treatment programme is based on the most up-to-date evidence available and is proven to 12 
be cost-effective in NHS settings28. We tailored the NCSCT treatment package to best suit the needs 13 
of the target population, and IAPT service. To optimise the likelihood of successful delievery of the 14 
smoking cessation intervention in these settings we altered the NCSCT standard treatment 15 
programme in three ways. 16 
 17 
1) We shortened the total treatment time from 110 minutes to 40 to 70 minutes to meet IAPT 18 
service requirements. It is possible that shortening treatment time may limit the effectiveness of the 19 
intervention. However, a recent Cochrane review found no clear evidence that decreasing the 20 
duration of personal contact time altered the effect of combined behavioural and pharmacological 21 
treatment for smoking cessation 48. There is an association between number of contacts offered for 22 
cessation and increased chances of quitting, however a Cochrane review found that this is not a dose 23 
response relationship, and that offering four or more contacts was more effective than offering 24 
three or fewer contacts 49; therefore participants will in our study be receiving an adequate number 25 
of contacts (i.e., 6 IAPT treatment appointments).  26 
 27 
2) Carbon monoxide (CO) monitoring will not be part of the intervention in one of the sites, as IAPT 28 
care is telephone-based in one of the two sites. During co-design we explored whether or not it was 29 
possible to use CO monitors in the behavioural programme, however feedback from PWPs and 30 
service managers was unanimous and indicated that it was not feasible to implement CO monitoring 31 
these settings. We cannot predict whether or not this will alter effectiveness of the smoking 32 
cessation intervention, and our pilot and feasibility study will not be large enough to explore the 33 
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impact of this on intervention delivery. However, if we find that the intervention is feasible, 1 
accepted and suitably implemented, this is something that we can adjust for in a definitive RCT.   2 
 3 
3) One aspect of this study that is not included in the NCSCT Standard Treatment Programme but will 4 
be added to the IAPT smoking cessation treatment will be psychoeducation about smoking and 5 
mental health. New evidence suggests that stopping smoking is associated with mental health 6 
benefits, potentially equivalent to taking anti-depressants24. This evidence can partially be explained 7 
by breaking the tobacco withdrawal cycle30,31. In summary, nicotine has a short half-life, and smokers 8 
start to experience the psychological symptoms of withdrawal soon after having a cigarette, for 9 
example symptoms of low mood and anxiety. Therefore, the smoker is in a constant state of 10 
withdrawal, with short periods of relief only when they are actively smoking and shortly after 11 
finishing a cigarette. It may be that smokers mistake the ability of tobacco to relieve withdrawal 12 
symptoms to its ability to relieve stress and low mood30,31. PWPs will integrate this evidence into 13 
treatment sessions. 14 
 15 
Conclusion  16 
This study is expected to lead to new insights on whether or not it is possible to deliver a 17 
collaboratively designed smoking cessation treatment programme alongside usual IAPT care as part 18 
of a holistic package of mental health treatment. This study will also help determine whether it is 19 
possible to evaluate the smoking cessation + IAPT intervention in a full randomised controlled trial.   20 
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